Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Sanofi's Genzyme Says MS Drug Lemtrada Shows More Trial Success

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2012 | 09:39pm CEST

Genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

In a Phase III trial called CARE-MS II involving 840 patients, the relapse rate was reduced by 49%, compared with an older drug called Rebif, or subcutaneous interferon beta-1a, which is sold by German rival Merck KGaA (>> Merck KGaA).

The company said 65% of patients treated with Lemtrada were relapse-free after two years into the study, compared with 47% treated with Rebif.

Genzyme is developing the drug, also known as alemtuzumab, in collaboration with German drug maker Bayer AG (>> Bayer AG), and Sanofi aims to launch the drug by the end of next year. Multiple sclerosis is a chronic disease that attacks the central nervous system.

"We believe these ground-breaking results from CARE-MS II, including reversal of disability accumulation in some patients, achieved over the standard therapy Rebif, provide a message of hope for people living with MS," said David Meeker, Genzyme's CEO, said in a statement, adding: "We are on track to submit alemtuzumab for review to U.S. and EU regulatory authorities in the second quarter of this year."

In the CARE-MS II trial, alemtuzumab was given as an injection eight times over the course of the two-year study. The first treatment course of alemtuzumab was administered on five consecutive days, and the second course was administered on three consecutive days 12 months later. Rebif was administered by injection three times per week, each week, throughout the two years of study.

Sanofi, which is struggling with patent expiries on its blockbuster drugs, bought Genzyme in February 2011 in a bid to widen its research net.

--By Sten Stovall, Dow Jones Newswires; +44 207 842 9292; sten.stovall@dowjones.com

Stocks mentioned in the article : Merck KGaA, Bayer AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
05:15p SANOFI : and Regeneron Announce FDA Approval of Dupixent (dupilumab), the First ..
11:07a VIVUS : to Regain Commercial Rights for Stendra from Sanofi
11:03a SANOFI : and Regeneron Announce FDA Approval of Dupixent (dupilumab), the First ..
10:56a SANOFI : Regeneron and Sanofi land the big one, winning FDA approval for their m..
03/28 SANOFI : Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXE..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28DJREGENERON PHARMACEUTICALS : FDA Approves Regeneron and Sanofi's Dupixent for Ecz..
03/28 SANOFI : and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First..
03/28 SANOFI : and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First..
03/28 SANOFI : Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), th..
More news
Sector news : Pharmaceuticals - NEC
02:38p FDA, Mylan silence on generic Advair may be good news for GSK
01:43p British business navigates rocky path to Brexit
09:52a ConvaTec's majority investors raise $1.2 billion via stake sale
03/28DJSenator McCaskill Begins Probe of Prescription Opioid Marketing -- 2nd Update
03/28DJSHIRE : Files 8K - Other Events
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09:20a Sanofi Needs Dupixent To Meet Lofty Expectations
08:28a Sanofi advancing toward sale of European generics unit
03/28 FDA OKs Regeneron and Sanofi's dermatitis med Dupixent
03/27 My Favorite Biotech Takeover Play
03/27 Sanofi gives up on ED med Stendra, returns rights to VIVUS
Advertisement
Financials (€)
Sales 2017 36 401 M
EBIT 2017 9 395 M
Net income 2017 5 592 M
Debt 2017 4 512 M
Yield 2017 3,55%
P/E ratio 2017 18,52
P/E ratio 2018 17,50
EV / Sales 2017 3,10x
EV / Sales 2018 2,97x
Capitalization 108 452 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 82,0 €
Spread / Average Target -2,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
Jérôme Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI9.15%117 271
JOHNSON & JOHNSON9.19%340 651
ROCHE HOLDING LTD.8.73%221 256
PFIZER INC.5.17%203 427
NOVARTIS AG-0.34%196 620
MERCK & CO., INC.7.59%173 904
More Results